In BV-2 microglia stimulated with S1, SKF 86002 at 1 µM reduced TNF-α production by ~ 47.9% compared with S1 alone. In kinase testing using ATF-2 as substrate and DMSO as control, SKF 86002 had no effect on the γ and δ isoforms. [1,2]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Reduced TNF-α production in stimulated microglia
Cell-based study · BV-2 microglia [1]
BV-2 microglia were pre-treated with SKF 86002 at 1 µM before stimulation with S1 at 100 ng/ml. TNF-α production was reduced by ~ 47.9% compared with S1 alone.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 µM
- Exposure duration
- 60 min prior to stimulation with S1 (100 ng/ml) for a further 24-h period
- Method
- pre-treating
- Co-treatment
- Other interventions in this design: S1 100 ng/ml. Compound effect isolated by the comparison: compared with S1 alone.
- Reported limits
- Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: SKF 86002
The paper names SKF 86002 without stating the salt or form; not verified as the dihydrochloride form supplied as A11101. No dose conversion or lot validation.
Materials and Methods > Effects of BAY11-7082, CRID3 and SKF 86002 on S1-Induced Neuroinflammation (S43); Results > S1 Activated p38 MAP Kinase in BV-2 Microglia (S130)
TNF-α production: TNF-α production; comparator: S1 alone — Results > S1 Activated p38 MAP Kinase in BV-2 Microglia (S130)
No Effect Reported on γ and δ Isoforms
Cell-based study · p38γ [2]
In the p38γ model, the inhibitor was added before the ATF-2 substrate, with DMSO as the control. No effect on the γ and δ isoforms was reported.
Literature-Reported Treatment Conditions
- Exposure duration
- 30 min at 37°C
- Method
- Before adding the ATF-2 protein as a substrate to the kinase reaction the inhibitors or DMSO (control) were added.
- Vehicle
- DMSO
- Reported limits
- Not stated in the sentences used: dose.
Methods and source locations
Compound reported in the paper: SKF 86002
The paper names SKF 86002 without stating the salt or form; not verified as the dihydrochloride form supplied as A11101. No dose conversion or lot validation.
Materials and Methods > In Vitro p38 and JNK Kinase Assay and Western Blot Analysis of Flag-tagged Protein (S102, S103); Results > The Effect of p38 Inhibitors SB203580 and SKF86002 on the Various p38 Isoforms Expressed in α2-Transfected Saos-2 Cells (S197, S200); Figure 7 legend (S251, S255, S256)
Levels of phosphorylated ATF-2: Levels of phosphorylated ATF-2; comparator: DMSO (control) — Results > The Effect of p38 Inhibitors SB203580 and SKF86002 on the Various p38 Isoforms Expressed in α2-Transfected Saos-2 Cells (S200); Figure 7 legend (S256)
